<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33063909</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>31</StartPage><EndPage>39</EndPage><MedlinePgn>31-39</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27091</ELocationID><Abstract><AbstractText>An orally administered, fixed-dose coformulation of sodium phenylbutyrate-taurursodiol (PB-TURSO) significantly slowed functional decline in a randomized, placebo-controlled, phase 2 trial in ALS (CENTAUR). Herein we report results of a long-term survival analysis of participants in CENTAUR. In CENTAUR, adults with ALS were randomized 2:1 to PB-TURSO or placebo. Participants completing the 6-month (24-week) randomized phase were eligible to receive PB-TURSO in the open-label extension. An all-cause mortality analysis (35-month maximum follow-up post-randomization) incorporated all randomized participants. Participants and site investigators were blinded to treatment assignments through the duration of follow-up of this analysis. Vital status was obtained for 135 of 137 participants originally randomized in CENTAUR. Median overall survival was 25.0 months among participants originally randomized to PB-TURSO and 18.5 months among those originally randomized to placebo (hazard ratio, 0.56; 95% confidence interval, 0.34-0.92; P = .023). Initiation of PB-TURSO treatment at baseline resulted in a 6.5-month longer median survival as compared with placebo. Combined with results from CENTAUR, these results suggest that PB-TURSO has both functional and survival benefits in ALS.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Muscle &amp; Nerve published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0505-1168</Identifier><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hendrix</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pentara Corporation, Millcreek, Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Samuel P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Pentara Corporation, Millcreek, Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knowlton</LastName><ForeName>Newman</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Pentara Corporation, Millcreek, Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macklin</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elliott</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Swedish Neuroscience Institute, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maiser</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Medicine, Hennepin Healthcare, Minneapolis, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karam</LastName><ForeName>Chafic</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Oregon Health &amp; Science University, Portland, Oregon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caress</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owegi</LastName><ForeName>Margaret Ayo</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quick</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Ohio State University College of Medicine, Columbus, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wymer</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Florida College of Medicine, Gainesville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goutman</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0001-8780-6637</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heitzman</LastName><ForeName>Daragh</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Texas Neurology, Dallas, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heiman-Patterson</LastName><ForeName>Terry D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Carlayne E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Neurology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothstein</LastName><ForeName>Jeffrey D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Brain Science Institute and Department of Neurology, Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasarskis</LastName><ForeName>Edward J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Kentucky College of Medicine, Lexington, Kentucky.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>California Pacific Medical Center Research Institute and Forbes Norris MDA/ALS Research and Treatment Center, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jenkins</LastName><ForeName>Liberty</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>California Pacific Medical Center Research Institute and Forbes Norris MDA/ALS Research and Treatment Center, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladha</LastName><ForeName>Shafeeq</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Gregory W. Fulton ALS Center, Barrow Neurological Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine in St. Louis, St. Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scelsa</LastName><ForeName>Stephen N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mount Sinai Beth Israel, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vu</LastName><ForeName>Tuan H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fournier</LastName><ForeName>Christina N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Pathology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Pathology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kristin M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ochsner Health System, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swenson</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Iowa Carver College of Medicine, Iowa City, Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goyal</LastName><ForeName>Namita A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Irvine School of Medicine, Irvine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pattee</LastName><ForeName>Gary L</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>Neurology Associates, Lincoln, Nebraska.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andres</LastName><ForeName>Patricia L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Independent Consultant, Nobleboro, Maine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babu</LastName><ForeName>Suma</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chase</LastName><ForeName>Marianne</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dagostino</LastName><ForeName>Derek</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Meghan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Gregory W. Fulton ALS Center, Barrow Neurological Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kittle</LastName><ForeName>Gale</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Gregory W. Fulton ALS Center, Barrow Neurological Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eydinov</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGovern</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostrow</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pothier</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Randall</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Gregory W. Fulton ALS Center, Barrow Neurological Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shefner</LastName><ForeName>Jeremy M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Gregory W. Fulton ALS Center, Barrow Neurological Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherman</LastName><ForeName>Alexander V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St Pierre</LastName><ForeName>Maria E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tustison</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vigneswaran</LastName><ForeName>Prasha</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wittes</LastName><ForeName>Janet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Statistics Collaborative, Inc., Washington, District of Columbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Zi-Fan</ForeName><Initials>ZF</Initials><AffiliationInfo><Affiliation>Statistics Collaborative, Inc., Washington, District of Columbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Amylyx Pharmaceuticals, Inc., Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klee</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Amylyx Pharmaceuticals, Inc., Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leslie</LastName><ForeName>Kent</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Amylyx Pharmaceuticals, Inc., Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Harvard University, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeramian</LastName><ForeName>Patrick D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Amylyx Pharmaceuticals, Inc., Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schoenfeld</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001414</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001420</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010654">Phenylbutyrates</NameOfSubstance></Chemical><Chemical><RegistryNumber>516-35-8</RegistryNumber><NameOfSubstance UI="D013655">Taurochenodeoxycholic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>60EUX8MN5X</RegistryNumber><NameOfSubstance UI="C031655">ursodoxicoltaurine</NameOfSubstance></Chemical><Chemical><RegistryNumber>7WY7YBI87E</RegistryNumber><NameOfSubstance UI="C075773">4-phenylbutyric acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2021 Jun;17(6):327</RefSource><PMID Version="1">33931772</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010654" MajorTopicYN="N">Phenylbutyrates</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013655" MajorTopicYN="N">Taurochenodeoxycholic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013995" MajorTopicYN="N">Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CENTAUR</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword><Keyword MajorTopicYN="N">sodium phenylbutyrate-taurursodiol</Keyword><Keyword MajorTopicYN="N">survival analysis</Keyword></KeywordList><CoiStatement>S. Paganoni reports grants from Amylyx Pharmaceuticals, Inc, The ALS Association, and ALS Finding A Cure during the conduct of the study, and grants from Revalesio, Ra Pharma, Biohaven, Clene Nanomedicine, and Prilenia, outside the submitted work. S. Hendrix reports other personal fees from Pentara Corporation, outside the submitted work. S.P. Dickson reports other personal fees from Pentara outside the submitted work. E.A. Macklin reports grants from Amylyx, The ALS Association, and ALS Finding A Cure Foundation during the conduct of the study. He is also a data and safety monitoring board member (DSMB) and reports grants from Acorda Therapeutics; steering committee membership for Biogen; consultant work for Cerevance; grants from GlaxoSmithKline; consultant work for Inventram, Lavin Consulting, and Myolex; grants from Mitsubishi Tanabe Pharmaceuticals; and DSMB membership for Novartis Pharmaceuticals and Shire Human Genetic Therapies, outside the submitted work. J.D. Berry reports grants from ALS Finding A Cure, The ALS Association, and Amylyx during the conduct of the study; personal fees from Biogen and Clene Nanomedicine; and grants from Alexion, Biogen, MT Pharma of America, Anelixis Therapeutics, Brainstorm Cell Therapeutics, Genentech, nQ Medical, National Institute of Neurological Disorders and Stroke, and the Muscular Dystrophy Association, outside the submitted work. M.A. Elliott has received personal fees from Amylyx and personal fees from Biogen. C. Karam reports grants and personal fees from Akcea, Alnylam, and Genzyme, and personal fees from Acceleron, Biogen, Alexion, Argenx, Cytokinetics, and CSL Behring, outside the submitted work. J.B. Caress reports grants from Amylyx during the conduct of the study, and grants from Orion Pharmaceuticals, MTB Pharma, and Cytokinetics, outside the submitted work. J. Wymer reports grants from Amylyx during the conduct of the study. S.A. Goutman reports grants from The ALS Association during the conduct of the study; grants from the National Institutes of Health/National Institutes of Environmental Health Sciences, The ALS Association, and Target ALS, outside the submitted work; consultant work for Biogen and ITF Pharma, outside the submitted work; and personal fees from Biogen, ITF Pharma, Watermark Research Partners, and for expert testimony, outside the submitted work. T.D. Heiman&#x2010;Patterson reports grants from Mitsubishi Tanabe Pharma America, Amylyx Pharmaceuticals, The ALS Association, and Orion Pharma, and personal fees from Cytokinetics, ITF, and Biohaven, outside the submitted work. C.E. Jackson reports grants from Amylyx during the conduct of the study; grants and personal fees from Cytokinetics, personal fees from CSL Behring, grants and personal fees from Mitsubishi Tanabe Pharma America, DSMB membership, and personal fees from Brainstorm and Mallinckrodt during the conduct of this study; and personal fees from ITF Pharma, outside the submitted work. C. Quinn received personal fees for serving on an advisory board of Amylyx, outside the submitted work. J.D. Rothstein reports licensing agreement and nonfinancial support from Ionis Pharmaceuticals; nonfinancial support from Calico, Biogen, and IBM Watson; research grant support from the National Institute of Neurological Disorders and Stroke, National Institute on Aging, Department of Defense, the Chan Zuckerberg Initiative, Microsoft, The ALS Association, the Muscular Dystrophy Association, Target ALS, F Prime, ALS Finding A Cure, Answer ALS, Robert Packard Center for ALS Research, GlaxoSmithKline, Travelers Insurance, American Airlines, Caterpillar, and the National Football League; and personal consulting fees from Expansion Therapeutics and Team Gleason. He also reports that his institution was a trial site and thus had a contract with Amylyx to participate in the study. J. Katz reports personal fees from MT Pharma America, Denali Pharmaceuticals, Genentech, and Calico, outside the submitted work. S. Ladha reports grants from Amylyx, Biogen, and MT Pharma, and personal fees from Amylyx and Biogen. T.M. Miller reports licensing agreement and nonfinancial support from Ionis Pharmaceuticals, a licensing agreement with C2N, grants and personal fees from Biogen, and personal fees from Cytokinetics and Disarm Therapeutics, outside the submitted work. S.N. Scelsa reports grants from Amylyx during the conduct of the study, and grants from Orion Pharma, outside the submitted work. T.H. Vu reports personal fees from the speakers bureau of Mitsubishi Tanabe Pharmaceuticals, and has participated in clinical trials sponsored by Amylyx, Orion, Biogen, Mallinckrodt, and Cytokinetics during the conduct of the study. J.D. Glass reports that his institution was a trial site and thus had a contract from Amylyx to participate in the study. A. Swenson reports research support from Amylyx, The ALS Association, Massachusetts General Hospital, the National Institutes of Health/National Institute of Neurological Disorders and Stroke, and serving on an independent data monitoring committee for Alexion. P.L. Andres reports personal fees from Amylyx for consulting during the conduct of the study and has an isometric strength testing apparatus (US Patent 7493812B2) held by the Hospital Corporation. S. Babu reports research support from the American Academy of Neurology, the AANEM Foundation, The ALS Association, the Muscular Dystrophy Association, Biogen, Orion, Voyager Therapeutics, and Novartis. M. Chase reports grants to the Massachusetts General Hospital (MGH) from The ALS Association, grants to the MGH from ALS Finding A Cure, and fee for service from Amylyx during the conduct of the study. M. Hall reports grants for funding for clinical trial monitoring and outcomes training support from The ALS Association and Amylyx during the conduct of the study. G. Kittle reports grants from The ALS Association and Amylyx during the conduct of the study. J.M. Shefner reports grants and personal fees from Amylyx during the conduct of the study; personal fees for consulting work from Cytokinetics and Brainstorm; grants and personal fees for outcomes training and study design from Mitsubishi Pharma America, outside the submitted work; personal fees for consulting from Neurosense and Otsuka, outside the submitted work; and grants for outcomes training from Alexion, Medicinova, and Biogen, outside the submitted work. He is also Neuromuscular section editor for UpToDate. J. Wittes and Z.&#x2010;F. Yu report payments from Amylyx to their employer during the conduct of the study. J. Cohen and J. Klee report a relationship with Amylyx during the conduct of the study, and they serve as co&#x2010;CEOs of Amylyx, outside the submitted work, with multiple patents issued to Amylyx. K. Leslie reports being full&#x2010;time employee of Amylyx during the conduct of the study, and personal fees from Amylyx, outside the submitted work. R.E. Tanzi reports personal fees from Amylyx outside the submitted work; has helped with inception and design of the clinical trial but was not involved with running the trial and had no contact with the trial subjects; and owns founding equity in Amylyx and serves as head of the company's scientific advisory board. W. Gilbert was director of Amylyx during the conduct of the study and a company shareholder. P.D. Yeramian reports full&#x2010;time employment at Amylyx during the conduct of the study. D. Schoenfeld reports grants from The ALS Association, during the conduct of the study, and personal fees from Immunitypharma and Alexion, outside the submitted work. M.E. Cudkowicz reports grants from Massachusetts General Hospital during the conduct of the study; grants from Clene Nanomedicine, Ra Pharma, Biohaven, and Prilenia, outside the submitted work; and personal fees from Takeda, Biogen, Sunovian, Cytokinetics, and Immunity Pharma, outside the submitted work. The remaining authors declare no potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>16</Day><Hour>8</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33063909</ArticleId><ArticleId IdType="pmc">PMC7820979</ArticleId><ArticleId IdType="doi">10.1002/mus.27091</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al&#x2010;Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162&#x2010;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong W. The role of managed care professionals in improving care for patients with ALS. Am J Manag Care. 2020;26(suppl 9):S198&#x2010;S205.</Citation><ArticleIdList><ArticleId IdType="pubmed">32840333</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V, ALS/Riluzole Study Group . A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330:585&#x2010;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. ALS/Riluzole study group&#x2010;II. Dose&#x2010;ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347:1425&#x2010;1431.</Citation><ArticleIdList><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Jackson CE, Heiman&#x2010;Patterson TD, Bettica P, Brooks BR, Pioro EP. Real&#x2010;world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;1&#x2010;10. 10.1080/21678421.2020.1771734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1771734</ArticleId><ArticleId IdType="pubmed">32573277</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G, et al. Confirmatory double&#x2010;blind, parallel&#x2010;group, placebo&#x2010;controlled study of efficacy and safety of edaravone (MCI&#x2010;186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610&#x2010;617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group . Edaravone (MCI&#x2010;186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double&#x2010;blind, placebo&#x2010;controlled trial. Lancet Neurol. 2017;16:505&#x2010;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard&#x2010;Marissal N, Chrast R, Schneider BL. Endoplasmic reticulum and mitochondria in diseases of motor and sensory neurons: a broken relationship? Cell Death Dis. 2018;9:333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5832431</ArticleId><ArticleId IdType="pubmed">29491369</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau DHW, Hartopp N, Welsh NJ, et al. Disruption of ER&#x2010;mitochondria signalling in fronto&#x2010;temporal dementia and related amyotrophic lateral sclerosis. Cell Death Dis. 2018;9:327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5832427</ArticleId><ArticleId IdType="pubmed">29491392</ArticleId></ArticleIdList></Reference><Reference><Citation>Manfredi G, Kawamata H. Mitochondria and endoplasmic reticulum crosstalk in amyotrophic lateral sclerosis. Neurobiol Dis. 2016;90:35&#x2010;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4754163</ArticleId><ArticleId IdType="pubmed">26282323</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho JA, Zhang X, Miller GM, Lencer WI, Nery FC. 4&#x2010;Phenylbutyrate attenuates the ER stress response and cyclic AMP accumulation in DYT1 dystonia cell models. PLoS One. 2014;9:e110086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4224384</ArticleId><ArticleId IdType="pubmed">25379658</ArticleId></ArticleIdList></Reference><Reference><Citation>Dion&#xed;sio PA, Amaral JD, Ribeiro MF, Lo AC, D'Hooge R, Rodrigues CM. Amyloid&#x2010;&#x3b2; pathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset. Neurobiol Aging. 2015;36:228&#x2010;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">25443293</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusaczuk M. Tauroursodeoxycholate&#x2014;bile acid with chaperoning activity: molecular and cellular effects and therapeutic perspectives. Cells. 2019;8:1471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6952947</ArticleId><ArticleId IdType="pubmed">31757001</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricobaraza A, Cuadrado&#x2010;Tejedor M, P&#xe9;rez&#x2010;Mediavilla A, Frechilla D, Del R&#xed;o J, Garc&#xed;a&#x2010;Osta A. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology. 2009;34:1721&#x2010;1732.</Citation><ArticleIdList><ArticleId IdType="pubmed">19145227</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu H, Smith K, Camelo SI, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti&#x2010;apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem. 2005;93:1087&#x2010;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">15934930</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiley JC, Pettan&#x2010;Brewer C, Ladiges WC. Phenylbutyric acid reduces amyloid plaques and rescues cognitive behavior in AD transgenic mice. Aging Cell. 2011;10:418&#x2010;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">21272191</ArticleId></ArticleIdList></Reference><Reference><Citation>Leslie K, Cohen J, Klee J, Valsecchi F, Manfredi G. AMX0035, a novel combination therapeutic candidate for treatment of primary mitochondrial diseases. Poster presented at: 2017 MDA Scientific Conference, March 19&#x2010;22, 2017, Arlington, VA. 2017.</Citation></Reference><Reference><Citation>Cudkowicz ME, Andres PL, Macdonald SA, et al. Northeast ALS and National VA ALS Research Consortiums. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler. 2009;10:99&#x2010;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">18688762</ArticleId></ArticleIdList></Reference><Reference><Citation>Elia AE, Lalli S, Monsurr&#xf2; MR, et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2016;23:45&#x2010;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024041</ArticleId><ArticleId IdType="pubmed">25664595</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate&#x2010;taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919&#x2010;930.</Citation><ArticleIdList><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>
NEALS Central Institutional Review Board
. Northeast Amyotrophic Lateral Sclerosis Consortium. https://www.neals.org/for-als-researchers/central-irb-master-contracts. Accessed September 3, 2020.</Citation></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on motor neuron diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2010;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow&#x2010;volume curve with growth and aging. Am Rev Respir Dis. 1983;127:725&#x2010;734.</Citation><ArticleIdList><ArticleId IdType="pubmed">6859656</ArticleId></ArticleIdList></Reference><Reference><Citation>Labra J, Menon P, Byth K, Morrison S, Vucic S. Rate of disease progression: a prognostic biomarker in ALS. J Neurol Neurosurg Psychiatry. 2016;87:628&#x2010;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">26152368</ArticleId></ArticleIdList></Reference><Reference><Citation>Daghlas I, Lever TE, Leary E. A retrospective investigation of the relationship between baseline covariates and rate of ALSFRS&#x2010;R decline in ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:206&#x2010;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">29260911</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AA, Fournier C, Polak M, et al. The Pooled Resource Open&#x2010;Access ALS Clinical Trials Consortium predicting disease progression in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2016;3:866&#x2010;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5099532</ArticleId><ArticleId IdType="pubmed">27844032</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J. Disease modification and neuroprotection in neurodegenerative disorders. Transl Neurodegener. 2017;6:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5613313</ArticleId><ArticleId IdType="pubmed">29021896</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur B, Bhat A, Chakraborty R, et al. Proteomic profile of 4&#x2010;PBA treated human neuronal cells during ER stress. Mol Omics. 2018;14:53&#x2010;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">29570205</ArticleId></ArticleIdList></Reference><Reference><Citation>Suaud L, Miller K, Panichelli AE, Randell RL, Marando CM, Rubenstein RC. 4&#x2010;Phenylbutyrate stimulates Hsp70 expression through the Elp2 component of elongator and STAT&#x2010;3 in cystic fibrosis epithelial cells. J Biol Chem. 2011;286:45083&#x2010;45092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3247989</ArticleId><ArticleId IdType="pubmed">22069317</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues CM, Steer CJ. The therapeutic effects of ursodeoxycholic acid as an anti&#x2010;apoptotic agent. Expert Opin Investig Drugs. 2001;10:1243&#x2010;1253.</Citation><ArticleIdList><ArticleId IdType="pubmed">11772248</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettori JR. Loss to follow&#x2010;up. Evid Based Spine Care J. 2011;2:7&#x2010;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3427970</ArticleId><ArticleId IdType="pubmed">22956930</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih W. Problems in dealing with missing data and informative censoring in clinical trials. Curr Control Trials Cardiovasc Med. 2002;3:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC134476</ArticleId><ArticleId IdType="pubmed">11985778</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronner LE, Podewils LJ, Peters A, et al. Impact of community tracer teams on treatment outcomes among tuberculosis patients in South Africa. BMC Public Health. 2012;12:621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3490985</ArticleId><ArticleId IdType="pubmed">22871071</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon JH, Elliott JH, Hong SY, Bertagnolio S, Jordan MR. Effects of physical tracing on estimates of loss to follow&#x2010;up, mortality and retention in low and middle income country antiretroviral therapy programs: a systematic review. PLoS One. 2013;8:e56047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3570556</ArticleId><ArticleId IdType="pubmed">23424643</ArticleId></ArticleIdList></Reference><Reference><Citation>Semeere A, Freeman E, Wenger M, et al. Updating vital status by tracking in the community among patients with epidemic Kaposi sarcoma who are lost to follow&#x2010;up in sub&#x2010;Saharan Africa. BMC Cancer. 2017;17:611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5581434</ArticleId><ArticleId IdType="pubmed">28865422</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, Yerramilli&#x2010;Rao P, Szymonifka J, et al. Analysis of start&#x2010;up, retention, and adherence in ALS clinical trials. Neurology. 2013;81:1350&#x2010;1355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3806927</ArticleId><ArticleId IdType="pubmed">24005339</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Cudkowicz M, Berry JD. Outcome measures in amyotrophic lateral sclerosis clinical trials. Clin Investig. 2014;4:605&#x2010;618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5305182</ArticleId><ArticleId IdType="pubmed">28203356</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>